Stimulating the growth of new neurons to replace those lost in Alzheimer's disease (AD) is an intriguing therapeutic possibility. But will the factors that cause AD allow the new neurons to thrive and function normally? Scientists at the Gladstone Institute of Neurological Disease (GIND) have discovered that two main causes of AD amyloid-beta (Aâ) peptides and apolipoprotein E4 (apoE4) impair the growth of new neurons born in adult brains.
What is more, they have identified drug treatments that can normalize the development of these cells even in the presence of Aâ or apoE4. The findings are described in two separate papers published in the current issue of Cell Stem Cell.
Although it had long been assumed that neurons cannot be renewed, it is now well established that new neurons are generated throughout the lives of mammals. One brain region in which new neurons are born in adults, the hippocampus, is involved in learning and memory and affected severely by Alzheimer's disease.
GIND investigator Li Gan, PhD, and her collaborators studied the development of neurons born in the hippocampus of adult mice genetically engineered to produce high levels of human Aâ in the brain. Surprisingly, Aâ initially accelerated the development of newborn neurons but then profoundly impaired their maturation at later stages of development.
"Interestingly," Dr. Gan said, "we were able to protect the newborn neurons and ensure their normal development with drugs that counteract Aâ-induced abnormalities in neural network activity. It is possible that these drugs could support the development of neurons from stem cells even in the hostile environment of the AD brain."
In a complementary study, GIND investigator Yadong Huang, MD, PhD and his team focused on apoE4, the major genetic risk factor for AD. The team used genetically engineered mice to study the effects of different human apoE variants on the maturation of neural stem cells or progenitor cells, from which new neurons develop in the adult brain. They found that apoE4 also impairs the development of new neurons in the hippocampus and identified drug treatments that could block these detrimental effects.
"Our findings suggest that apoE4 inhibits the development of newborn neurons by impairing specific signaling pathways and that boosting these pathways with drugs may be of therapeutic benefit," said Dr. Huang. "It might allow us to encourage the development of new neurons from stem cells to replace those lost in apoE4 carriers with AD."
"Although stem cell therapy for AD is still a long ways off, these studies have identified strategies to overcome major obstacles in the path towards this goal," said GIND Director Lennart Mucke, MD, who coauthored one of the studies. "They clearly demonstrate that drugs can be used to improve the development of newborn neurons in memory centers of the adult brain, even in the presence of toxic factors widely presumed to cause AD."
Dr. Gan's research was supported by the J. David Gladstone Institutes and the L.K.Whittier Foundation. Binggui Sun, Brian Halabisky, Yungui Zhou, Jorge Palop, Guiqiu Yu, and Lennart Mucke also contributed to this research. Dr. Huang's research was supported by the J. David Gladstone Institutes, the California Institute for Regenerative Medicine, and the National Institutes of Health. Gang Li, Nga Bien-Ly, Yaisa Andrews-Zwilling, Aubrey Bernardo, Karen Ring, Brian Halabisky, Changhui Deng, and Robert W. Mahley also contributed to this research.
Dr. Gan's and Dr. Huang's primary affiliations are with the Gladstone Institute of Neurological Disease where their laboratories are located and all of their research is conducted. Dr. Gan is also Assistant Professor of Neurology and Dr. Huang is Associate Professor of Pathology and Neurology at the University of California, San Francisco.
In addition to his primary affiliation as Director of the Gladstone Institute of Neurological Disease, Dr. Mucke is the Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco.
About the Gladstone Institutes
The Gladstone Institutes is a nonprofit, independent research and educational institution, consisting of the Gladstone Institute of Cardiovascular Disease, the Gladstone Institute of Virology and Immunology and the Gladstone Institute of Neurological Disease. Independent in its governance, finances and research programs, Gladstone shares a close affiliation with UCSF through its faculty, who hold joint UCSF appointments.
Valerie Tucker | EurekAlert!
Brought to light – chromobodies reveal changes in endogenous protein concentration in living cells
21.09.2018 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen
A one-way street for salt
21.09.2018 | Julius-Maximilians-Universität Würzburg
The building blocks of matter in our universe were formed in the first 10 microseconds of its existence, according to the currently accepted scientific picture. After the Big Bang about 13.7 billion years ago, matter consisted mainly of quarks and gluons, two types of elementary particles whose interactions are governed by quantum chromodynamics (QCD), the theory of strong interaction. In the early universe, these particles moved (nearly) freely in a quark-gluon plasma.
This is a joint press release of University Muenster and Heidelberg as well as the GSI Helmholtzzentrum für Schwerionenforschung in Darmstadt.
Then, in a phase transition, they combined and formed hadrons, among them the building blocks of atomic nuclei, protons and neutrons. In the current issue of...
Thin-film solar cells made of crystalline silicon are inexpensive and achieve efficiencies of a good 14 percent. However, they could do even better if their shiny surfaces reflected less light. A team led by Prof. Christiane Becker from the Helmholtz-Zentrum Berlin (HZB) has now patented a sophisticated new solution to this problem.
"It is not enough simply to bring more light into the cell," says Christiane Becker. Such surface structures can even ultimately reduce the efficiency by...
A study in the journal Bulletin of Marine Science describes a new, blood-red species of octocoral found in Panama. The species in the genus Thesea was discovered in the threatened low-light reef environment on Hannibal Bank, 60 kilometers off mainland Pacific Panama, by researchers at the Smithsonian Tropical Research Institute in Panama (STRI) and the Centro de Investigación en Ciencias del Mar y Limnología (CIMAR) at the University of Costa Rica.
Scientists established the new species, Thesea dalioi, by comparing its physical traits, such as branch thickness and the bright red colony color, with the...
Scientists have succeeded in observing the first long-distance transfer of information in a magnetic group of materials known as antiferromagnets.
An international team of researchers has mapped Nemo's genome, providing the research community with an invaluable resource to decode the response of fish to...
21.09.2018 | Event News
03.09.2018 | Event News
27.08.2018 | Event News
21.09.2018 | Physics and Astronomy
21.09.2018 | Life Sciences
21.09.2018 | Event News